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Several glycoproteins or polypeptides that are produced by T  cells in culture 
(T lymphokines) and that inhibit cell proliferation in vitro have been identified 
and characterized. Two of these factors, immune interferon (IFN-3') (1-3) and 
one  member of the  lymphotoxin  (LT) 1 family  (4-6),  have  been  purified  to 
homogeneity, cloned, and sequenced (1-3, 7, 8). Several others are at different 
stages of characterization and, based on their most prominent biological activity, 
have been designated: inhibitor of DNA synthesis (IDS) (9-I I); suppressor cell 
induction factor (SIF) (12,  13);  macrophage migration inhibitory factor (MIF) 
(4,  14); soluble immune suppressor supernatants (SISS-T and SISS-B)  (15,  16), 
which inhibit T cell proliferation or B cell Ig production; B cell growth inhibitory 
factor (BIF) (17);  suppressor activating factor (SAF) (18,  19);  soluble immune 
response suppressor (SIRS) (20-23);  a  factor that inhibits mouse bone marrow 
and leukemia cell proliferation (STIF) (24);  and colony-inhibiting lymphokine 
(CIL), a factor that inhibits colony formation of human bone marrow progenitor 
cells (25).  Several of these factors (LT, BIF, SISS-B,  CIL) have been shown by 
column chromatography to have M, of 70,000-90,000,  and their possible unique 
identity has been attributed either to their specific physicochemical characteristics 
(heat and pH sensitivity) or to their spectrum of target reactivity. 
Part of the problem hampering the rapid purification and definitive charac- 
terization by protein and nucleic acid sequencing of these lymphokines lies  in 
the  fact  that  most  are produced  in  small  amounts  by short  term  cultures of 
human PBL stimulated to proliferate by mitogens or alloantigens. Some factors, 
however,  are  abundantly  elaborated  by  T  cell  lines:  SAF  is  produced  by  a 
subclone of the 6-thioguanine (6TG)-resistant human leukemic T  cell line CEM 
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(I 8), and CIL was  identified in  the supernatant of a  putative T  cell hybridoma 
between  the 6TG-resistant  T  leukemia cell  line Jurkat  and  mitogen-stimulated 
human  lymphocytes  (25).  However,  firm  evidence  that  the  producing  clone 
(MT1) is truly a  hybrid and not just a  subclone of  Jurkat cells is lacking because 
(a) only HLA surface markers of theJurkat cell line could be detected (25), and 
(b) analysis of the clone with a po]ymorphic probe (Pow 101) (D 14S 1) (26) showed 
a  restriction pattern type of the parental Jurkat cells and not of the lymphocytes 
used as fusion partners (our unpublished observations). 
We report here that all the T  leukemia cell lines tested constitutively produce 
high  concentrations  of a  factor  that  displays  potent  antiproliferative  effects 
against a  broad spectrum  of normal and  malignant cells of hemopoietic origin. 
The  biological  effects  of  this  T  leukemia-derived  suppressor  lymphokine 
(TLSL), as well as its physicochemical and M,- characteristics are presented. 
Materials and  Methods 
Cell Lines.  Seven established T  lympboblastoid cell lines were examined for sponta- 
neous  production of factors with antiproliferative activity. They included Jurkat  (27), 
CCRF/HSBz (28), CCRF/CEM (29), MOLT-4 (30), JM (31),  HPB-ALL (32), and HUT- 
78 (33).  All  of these lines originated from patients with acute T  cell leukemia, except 
HUT-78,  which  was  derived  from  a  patient  with  chronic T  cell  leukemia.  With  the 
exception of HPB-ALL cells, which showed a low level of micoplasma contamination, all 
of  the lymphokine producer cell lines were micoplasma-free, as determined by the methods 
of growth in agar (34) and the Hoechst DNA stain (35).  Target hemopoietic cell lines of 
non-T origin  included:  three Burkitt lymphoma-derived B lymphoblastoid lines (Raji, 
Daudi, and BL2) four myelogenous leukemia cell lines (HL60, ML3, KGI, and K562), 
the histiocytic lymphoma line U937, and tbe BV-173 line established from a patient with 
chronic myeloid leukemia (CML) in lymphoid blastic crisis (for review see 36). 
All of the cell lines described above were grown at 37°C in a  5% CO2 atmosphere in 
RPMI  1640 medium supplemented with  10%  heat-inactivated FBS (Flow  Laboratories, 
Rockville, MD), glutamine, and antibiotics. 
Lymphocyte Cultures.  Peripheral blood mononuclear cells  from healthy donors were 
separated by centrifugation on a Ficoll-Hypaque gradient and incubated in the presence 
of 1% PHA (Burroughs Wellcome, Greenville, NC) or 0.5% PWM (Gibco, Grand Island, 
NY). MLC were performed by mixing freshly separated PBL with allogeneic "y-irradiated 
(4,500 rad)  PBL at a  responder/stimulator ratio of 1:1  or  1:2  in  RPMI  1640 medium 
containing  15%  heat-inactivated human  AB serum.  MLC and  mitogen-stimulated PBL 
were used as targets to investigate the susceptibility of in vitro-activated hemopoietic cells 
to the T  cell leukemia-derived suppressor lymphokine. In some of the assays, purified T 
cells were stimulated with PHA or in MLC and used as targets as compared to unfraction- 
ated PBL; purified T  lymphocytes were obtained after depletion of monocytes, B, and 
null cells by adherence to plastic, phagocytosis of carbonyl iron particles, adherence to 
nylon wool columns, and depletion of non-E rosetting cells, as described elsewhere (37). 
Myeloid and Erythroid Progenitor Cells.  Bone marrow and peripheral blood mononu- 
clear cells from healthy donors were separated on Ficoll/Hypaque gradients. Both samples 
were depleted of adherent cells  by two incubations of 60 min each in  plastic flasks  in 
RPMI medium containing 20% FBS at a concentration of 5-10 X 10  6 cells/ml. Peripheral 
blood CFU-GM and BFU-E were further depleted of monocytes and B cells by passage 
on nylon wool columns, and were depleted of T lympbocytes by elimination of E-rosetting 
cells  as described previously (37).  The rosetting technique with  neuraminidase-treated 
sheep E was repeated twice to obtain ~99%  depletion of T  cells.  Phagocytic cells  were 
then removed by carbonyl iron treatment, as described (37). 
Production and Fractionation of TLSL  3-4 d after their passage, exponentially growing 
T  leukemia cell lines were centrifuged at 3,500 rpm for 20 rain at 4°C, and the cell-free 2O  A  T  CELL  LEUKEMIA-DERIVED SUPPRESSOR  LYMPHOKINE 
supernatants (SPN) were harvested. For gel filtration, cells were grown in 500 ml of tissue 
culture medium to a density of 1-2 ×  106 cells]ml, transferred to either 1 liter of serum- 
free synthetic medium  (38) or to RPM1  medium containing 5%  FBS, and incubated  at 
37°C in a  CO2-enriched  humidified atmosphere  for either  5  or 2  d, respectively.  Cell- 
free  crude  SPN  were  harvested,  solid  ammonium  sulfate  was  added  to  achieve  85% 
saturation, and the solution was equilibrated  for 20 rain before centrifugation at  13,200 
g for 20 min at 4°C. The resultant precipitate was resuspended in PBS placed in dialysis 
tubing (Spectrapor; Spectrum Medical Industries, Los Angeles, CA) and dialyzed exten- 
sively at  4°C against PBS or PBS plus 0.5 M  NaCI, or PBS plus 0.02%  Tween-20 (Bio- 
Rad Laboratories, Richmond, CA). The dialyzed material was centrifuged at  13,200 g for 
20 min at 4°C to remove large aggregates. A  4-ml aliquot was placed on a Sephacryl S- 
300 column (1.5 ×  50 cm; Pharmacia Fine Chemicals,  Piscataway, NJ) equilibrated  with 
PBS or PBS plus  0.5  M  NaCI, or PBS plus 0.02%  Tween-20,  and  3-ml fractions were 
collected at a  flow rate  of 10  rnl/h at  22°C.  Fractions  were  tested for antiproliferative 
activity as described below. 
Proliferation  Assay.  The  antiproliferative  activity present  in  the  crude and  partially 
purified SPN was measuredagainst a variety of target cells. Hemopoietic tumor cell lines 
were  seeded  in triplicate  wells of microtiter  plates at  2-4  x  10 ~ cells in  100  #l/well  in 
tissue culture medium, and 100 t~l/well of SPN at various concentrations was added. After 
a  5-d  incubation  at  37°C  (conditions  predetermined  to  give  maximal  inhibition  of 
proliferation without significant loss of cell viability) 2 •Ci  [~H]TdR (2 Ci/mmol) per well 
was  added.  The  cultures  were  harvested  7  h  later  on  fiberglass  filters,  and  isotope 
incorporation was measured by scintillation counting. Alternatively, cells were seeded in 
Linbro plates at 2-4 X 105 cells in 2 ml/well in the presence of several SPN concentrations; 
on day 5, the cells were counted and viability was monitored by Erythrosin B dye exclusion 
test. The cells were washed and transferred to microplates at 2 X 105 viable cells/well and 
[3H]TdR was added for 7 h to triplicate cultures. When mitogen- or alloantigen-stimulated 
lymphocytes were  used  as targets,  these  were  plated  at  a  concentration  of 1-2  x  10  ~ 
cells/well  in microtiter plates and incubated with lymphokine-containing SPN for 3-4 d 
(in the case of PHA-stimulated cells)  or for 6 d  (in the case of PWM- or MLC-stimulated 
cells) before addition of [3H]TdR. 
Clonogenic Assay.  Tumor cell  lines  were  incubated  at  5  ×  10  ~ cells]well  of Linbro 
plates in 2 ml medium containing 10-fold dilutions of T  cell leukemia-derived SPN. On 
day 4, cells were monitored for viability and cell concentration. Cells were then seeded in 
plastic Petri dishes at 2  ×  l0  s in 0.9% methylcellulose (Dow Chemical Co. Midland,  MI) 
and  complete  medium  supplemented  with  10-fold  serial  dilutions  of crude  SPN.  The 
number  of  viable  colonies  was  determined  after  14-d  incubation  at  37°C,  and  was 
compared to the  growth  of suspension  cultures  incubated  in microplates  for the  same 
length of time. 
Culture Assay for CFU-GM and BFU-E.  Bone marrow and peripheral  blood CFU-GM 
were cultured,  as previously described (25), in  35-ram  Petri  dishes in Iscove's modified 
Dulbecco's medium  containing 20%  FBS,  0.3%  agar,  10%  Giant  Cell  Tumor cell  line 
(GCT)-conditioned medium (Gibco) as a  source of colony stimulating factor (CSF), and 
different concentrations of T  leukemia-derived  SPN. Colony growth of late (less  imma- 
ture) and early (more immature) CFU-GM was monitored after 7 and 14 d of incubation, 
respectively, at 37 °C in a  5% CO2 atmosphere. 
BFU-E were  cultured,  as  previously described  (25),  in  Iscove's modified  Du[becco's 
medium containing 0.8% methylcellulose, 30% FBS, 7% lymphocyte-conditioned medium 
(obtained from human PBL cultured for 7 d in the presence of PHA) as a source of burst- 
promoting activity (BPA), 10  -4 M/3-mercaptoethanol,  1.5 U]ml sheep erythropoietin step 
3  (Connaught  Laboratories,  Ltd.,  Ontario,  Canada),  and  various  concentrations  of T 
leukemia-derived SPN. BFU-E-derived colonies were scored after  14 d of incubation. 
IFN Assay.  Antiviral titers were measured in the crude SPN and in the fractionated 
material by inhibition of the cytopathic effect of vesicular stomatitis virus on a variety of 
target fibroblast lines, including bovine brain (CB1), human fetal skin (FS-1, Ag-10, and 
Ag-1603) and human foreskin (HF) fibroblasts. The assay included the National Institutes SANTOLI  ET  AL.  21 
of Health human reference IFN G-023-901-527,  and the E.  coli-derived human  IFN-3, 
(Genentech, Inc., San Francisco,  CA) as standard IFN preparations (39). 
lnterleukin  2 (IL-2) Assay.  -The  levels of IL-2 present in the conditioned medium of T 
leukemia cell lines were measured by testing the ability of cell-free SPN to support the 
growth of IL-2-dependent human T  cell clones, as described elsewhere (40). 
DNA  Cell Cycle Analysis.  Cellular  DNA  of tumor  cell  lines  cultured  for  1-7  d  in 
medium  alone  or  in  the  presence of TLSL  was examined  by staining  the  cells with 
propidium  iodide (41).  Cells were seeded in T25 plastic flasks at 2  ×  105 cells/ml.  At 
various  intervals  after  addition  of  10%  crude  SPN,  cells  were  plated  as  5.0  X  l0  B 
cells/well,  fixed with  cold 70%  ethanol  for  10  min,  washed,  and  resuspended in  PBS 
containing  0.2 #g/ml propidium iodide and 62 #g/ml  RNase (Sigma Chemical  Co.,  St. 
Louis, MO). Cells were then examined by flow cytometry. 
Results 
Inhibition of Proliferation of Leukemia and Lymphoma Cell Lines.  The presence 
of antiproliferative activity in the T  cell leukemia-derived conditioned medium 
was  measured  by  monitoring  daily  the  cell  number,  viability,  and  [3H]TdR 
incorporation  of leukemia/lymphoma target cell lines incubated in the presence 
of crude  SPN.  Fig.  1  depicts  a  representative  experiment  in  which  Daudi, 
sensitive to all of the SPN, and  BV-173,  not inhibited  by the Jurkat  SPN  (see 
Table  I),  were used.  In the  first  5  d,  the  viability and  concentration  of Daudi 
cells incubated in the presence of either Jurkat or CCRF/CEM  SPN were very 
similar  to  those  in  control  cultures.  In  contrast,  [~H]TdR  incorporation  was 
already reduced on the third  day, especially in the cultures incubated with the 
CCRF/CEM  SPN.  By day  7,  the  treated  cells displayed very low viability and 
ability to incorporate  [3H]TdR, and by day 9,  they were all dead (Fig.  1).  BV- 
173 cells incubated with CCRF/CEM  SPN were still  90%  viable on day 5, but 
became much  less viable and  able to proliferate during  the following days.  In 
contrast,  the  viability,  concentration,  and  [3H]TdR  incorporation  of BV-173 
cells incubated in the presence of the Jurkat SPN were identical to those of the 
control  cultures  throughout  the  9-d  period  examined  (Fig.  1).  All  of  these 
observations demonstrate that the inhibitory activity of TLSL is cytostatic rather 
than cytotoxic. 
Because isotope incorporation  was the most sensitive indicator of inhibition, 
subsequent experiments were performed by seeding the experimental and con- 
trol cells directly in microplates and comparing [~H]TdR incorporation  on day 
5. Table I shows the spectrum of  reactivity of SPN from seven human T  leukemia 
cell lines against a panel of leukemia/lymphoma target cell lines. The SPN from 
Jurkat  cells strongly  inhibited  [3H]TdR  uptake  by two Burkitt  iymphoma  cell 
lines  (Raji  and  Daudi),  and  slightly  inhibited  the  growth  of another  Burkitt 
lymphoma  (BL2) and  of the  myeloblastic leukemia  KG1  cells;  the  other  SPN 
drastically  inhibited  [3H]TdR incorporation  of all  target  cells tested (Table  I). 
The myelogenous leukemia cell lines  HL60,  ML3, and  K562 were slightly less 
susceptible than  others to the inhibitory activity of most SPN. The production 
of TLSL was restricted to leukemia cell lines ofT cell origin: crude SPN obtained 
from  Raji and  U937  cells (Table  I) and  from  seven  other  cell  lines  of non-T 
origin (Daudi, BL2, K562, HL60, KG1, BV-173, ML3) (data not shown) did not 
inhibit the growth of any hemopoietic cell line tested. 
Titration  experiments  against  Raji  cells  (one  of the  most  sensitive  targets) 100 
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FrGURE  1.  Kinetics of inhibition of proliferation, Daudi and BV-173 cells were suspended at 
105 and 5  ×  104 cells/ml respectively, and incubated at 37°C in five separate tissue culture 
flasks in medium containing 10% crude SPN from Jurkat and CCRF/CEM cell lines, Control 
cukures were incubated in mediun~  with no inhibitory factors. On alternate days, atiquots of 
cells were removed from each flask and their concentration and viability were monitored. The 
cell concentration in each sample was adjusted to  106 cells/ml and [3H]TdR was added for 7 
h to triplicate cultures containing 2 X 105 cells/well. Neither fresh medium nor additional T 
leukemia-derived SPN was added during the entire 9-d incubation period. 
TABLE  I 
Antiproliferative Activity of T Cell Leukemia-derived SPN on Hemopoietic  Tumor Lines 
of Non-T Origin 
SPN  Raft  Daudi  BI,2  KG l  HL60  ML3  U937  K562  BV-173 
Jurkat  89.2*-+7.2  94.0--- 1.4  36.1 -+4.2  16.0-+4,3  -<1.0  ~1.0  -<1.0  ~:1.0  ~1.0 
CCRF/HSB~  95.6-+4,4  90.1±6.4  78.0 -+ 8,3  86.0-+0  63,0±8,5  78.5-+6.4  90.5+3,5  75.3-+3.8  95.7±4.2 
JM  97.0-+2,3  81.3±3.4  59.1-+3,7  89.0-+5.3  66.3-+5.7  84.5-+2.1  88.4+1,7  79.4 ±  1.8  84.5±9.2 
HPB-AI.I.  96.2 -+ 2.6  96.4-+1.9  92.fi -+ 1.6  92.7-+2.l  87.6-+8.1  90.4±2.8  86,3-+4.6  75.2-.+2,1  89.7 ±  8.5 
MOI,T-4  95.8-+3.3  85.8-+8.8  91.0-+6.8  90,6-+5.0  68.0-+2.9  79.2±7,5  90,3"+3.8  88.0-.+1.4  88.7 ± 6,7 
HUT-78  97.8-+1.3  94,3-+4.1  96.9+2.5  95.3+4.0  92.3 -+ 7.1  90,5 -+ 9,4  96.6"+3,5  90.7-+2.7  94.5-+3.5 
CCRF/CEM  96.4-+1.5  97.2-+1.5  95.7-+3.8  91.0-+2.6  89.0-+5.3  93.3±74  88.5-+0.7  90.0-+5.1  96.5±2.7 
Raji  _< 1.0  -< 1.0  _~1.0  -  1.0  ~1.0  -- 1.0  ~ 1.0  ~1.0  -< 1,0 
U937  _<l.0  <1.0  ~1.0  ~1.0  ~1.0  -<1.0  ~1.0  <1.0  <1.0 
Target ceils  ,,,.ere seeded in microplates (2-4 ×  l0  s ceils/well) in  medium containing T  cell  leukemia-derived crude SPN (1:10 dilution). 
After a 5-d incubation at 37°C, [SH]TdR was added for 7 h, and incorporation was measured. 
* Values represent the percent inhibition of proliferation observed in 4-9 experiments (mean -.+. SD). SANTOLI  ET  AL.  23 
revealed that the SPN from CCRF/CEM, MOLT-4, and HUT-78 cells were the 
most inhibitory, being able to inhibit at very high dilutions (10-9-I0 -1"~) (Fig. 2); 
those derived from HPB-ALL, JM, and CCRF/HSBz cells had a strong inhibitory 
activity (>80%) up to dilutions of 10  -5, and the Jurkat SPN was the least active 
of all,  being  able  to  inhibit  only at  dilutions  lower  than  10  -5.  When  the  less 
susceptible K562 target cells were used, similar data were obtained, but the titer 
of each  SPN  was at  least  100  times lower, and  the Jurkat  SPN  was not active 
(Fig. 2). 
CIonogenic assays were performed to determine whether TLSL could abrogate 
the ability of malignant  targets to grow as clones in semisolid medium.  After a 
14-d incubation in methylcellulose, control cultures of Raji and Daudi cells were 
able to produce hundreds  of large colonies containing  viable cells.  In contrast, 
the cultures incubated in the presence of 1:10 dilution of either CCRF/CEM or 
HUT-78  SPN  formed  few  (_<10) small  clumps  containing  5-10  degenerated 
cells. The number and size of clumps or colonies became larger with increasing 
SPN  dilutions,  but  the  cells  were  mostly  dead;  at  the  highest  dilutions  used 
(10  -9-10  -~ ~) the number of colonies detected and their viability was ~50% that 
of the control  cultures.  The  reduction  in  c]onogenic efficiency induced by the 
SPN at any dilution  tested paralleled  the  inhibition  in  [3H]TdR incorporation 
observed in the cells incubated in microplates for the same length of time. These 
data indicate that the clonability of tumor cell lines in semisolid cultures is not 
affected during the first few days of incubation with TLSL.  Later on, however, 
cell  replication  is  arrested  and  the  elements  present  in  each  colony  undergo 
degenerative processes. 
Inhibition  of  proliferation  was  not  detected  in  T  cell  lines  during  a  5-d 
incubation  with  the T  leukemia-derived  SPN, with  two exceptions:  the Jurkat 
cell line, which was susceptible to every SPN, and the CCRF/HSB2 cell line, in 
which proliferation  was partially inhibited by SEN from CCRF/CEM, HUT-78, 
and MOLT-4 cells (Table II). Thus, the low-producer T  cell line Jurkat was the 
most susceptible to the inhibitory activity, the intermediate-producer  T  cell line 
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FIGURF  2.  Titration  of the  antiproliferative activity of TLSL.  Raji  and  K562  cells were 
seeded in triplicate cultures at 2  X  l0  "~ celts/well in medium containing 100-fold dilutions of 
crude SPN  from .lurkat  (O),  HUT-78  (Q),  C('RF]HSB2  (F-I), MOLT-4  (I),  HPB-ALL  (/X), 
CCRF/CEM  (A),  and JM (~) cell lines.  After a  5-d incubation at 37°C,  [SH]TdR was added 
and cells harvested  7  h  later.  The  percent  inhibition of isotope  incorporation  is  based on 
240,860 and 260,678 cpm of the control Raji and K562 cells, respectively. 24  A  T  CELL  LEUKEMIA-DERIVED  SUPPRESSOR  LYMPHOKINE 
TABLE  II 
Antiproliferative  Activity of T Cell Leukemia-derived  SPN on 
Hemopoietic Tumor Cell Lines of T Cell Origin 
SPN  Jurkat  CCRF/HSB2 
JM, HPB- 
ALL, 
MOLT-4, 
HUT-78, 
CCRF/ 
CEM 
Jurkat  <1.0"  _~ t .0  ~ 1.0 
CCRF/HSB2  55,5 _+  10.5  ~1.0  _~1.0 
JM  55.1  +  4.7  ~1,0  ~_1.0 
HPB-ALL  38.4 _+ 2.9  _~1,0  _~I.0 
MOLT-4  68.5 +  4,9  24.0 +  2,2  -<1.0 
HUT-78  81.3 +  8.8  46.2 +  11,3  _~1.0 
CCRF/CEM  80.3 +  8.6  74.6 +  3,2  _~1.0 
T  cell lines (2-4 X  10  ~ cells/well) were incubated in the presence of T 
leukemia-derived crude SPN (diluted  1:10) for 5 d  before addition of 
[aH]TdR, 
* Values represent percent inhibition of [~H]TdR incorporation (mean + 
SD) observed in three or four experiments. 
CCRF/HSB2 was partially sensitive, and the high-producer lines were not affected 
at all. In no instance did the SPN inhibit the proliferation of the cells from which 
they were derived (Table I1). However, partially purified and more concentrated 
material derived from the conditioned medium of the Jurkat cell line inhibited 
the growth of  Jurkat cells, as well as of the other T  cell lines that were insensitive 
to  the  crude  preparation  (data  not  shown).  Autologous pairs  of Epstein-Barr 
virus (EBV)-transformed B lymphoblastoid cell  fines and IL-2-dependent T  cell 
clones, all established in our laboratory from tbe blood of healthy donors, were 
used as  target cells  in  some experiments: the T  cell  clones were only slightly 
sensitive  to  the  inhibitory  activity  of the  crude  SPN,  whereas  their  B  cell 
counterparts were highly susceptible (data not shown). Under the same experi- 
mental conditions described above, neither HeLa cells nor mouse L fibroblasts 
were affected by the presence ofJurkat SPN at any dilution tested (10-1-10-9). 
The SPN  from CCRF/CEM cells  was  not effective against mouse L  cells but 
inhibited the proliferation of HeLa cells up to the 10  .9 dilution; by day 7, these 
cells were all detached from the plastic and had a viability 60-70%  lower than 
control HeLa cells. 
To determine whether the continuous presence of TLSL was required for the 
inhibitory effect, proliferation was compared in Raji and BV-173 cells that had 
been either cultured for 4-5 d in the presence of crude SPN or treated with the 
same SPN for shorter time periods. Results indicated that a  1-h incubation with 
TLSL was sufficient to result in significant inhibition of proliferation (up to 75% 
in the case of Raji and up to 69% in the case of BV-173 cells) (Table III). The 
levels of inhibition observed after 3  h,  7  h, or after overnight treatment were 
similar, and approached those observed in cultures continuously incubated with 
the SPN.  Thus,  reduced proliferative activity in  target cells  is observed even 
after a very brief exposure to TLSL, although its continuous presence results in SANTOLI  ET  AL.  25 
TABLE  III 
Kinetics of Inhibition  of Proliferation  of Tumor Cells Incubated with T Leukemia-derived SPN 
For Various  Time Periods 
SPN 
Raji cells plus SPN for:  BV-173 cells plus SPN for: 
1 h  3-16h  5d  1 h  3-16h  4d 
Medium  87,417"  83,083  84,021  12,356  16,461  17,624 
Jurkat  34,506 (61)  12,991  (84)  4,243 (95)  11,905 (4)  17,103 (0)  18,303 (0) 
CCRF/HSB2  42,907 (51)  15,041  (82)  2,295 (97)  10,437 (16)  8,795 (47)  3,453 (81) 
JM  36,724 (58)  17,150 (80)  1,706(98)  NT*  NT  NT 
HPB-ALL  28,411 (68)  5,376 (94)  1,098 (99)  3,891  (69)  1,608 (90)  1,698 (90) 
MOLT-4  25,743 (71)  10,789 (87)  1,841  (98)  NT  NT  NT 
HUT-78  21,919 (75)  6,224 (93)  1,143 (99)  NT  NT  NT 
CCRF/CEM  26,776 (70)  16,140 (81)  1,947 (98)  5,946 (52)  3,291 (80)  1,634 (91) 
Raji and BV-173 cells were incubated at 37°C in 24-well Linbro plates for 1, 3, 7, and 16 h in the 
presence or absence of crude SPN (1:10 dilution); the cells were washed four or five times after 
each interval, and incubated in microplates (2 ×  103 cells/well in triplicate) for a total of 4-5 d in 
medium alone.  Cultures that were incubated continuously in the presence  of crude SPN over a 
period of 4-5 d were seeded  directly  in microplates  (2 ×  10  s cells/well) from day 0. Cells were 
harvested after a 7-h pulse with [SH]TdR. 
* Data are given as mean cpm. The number in parentheses  is the percent inhibition  of proliferation. 
* NT, not tested. 
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FIGURE 3.  Titration of the antiproliferative  activity of TLSL after adsorption to target cells. 
Undiluted CCRF/CEM  SPN was added to Raji cells (1 ml SPN for 1.5 x  l0  s cells) in plastic 
tubes. After a 1-h incubation at 37°C or 4°C, the cells were spun at 3,000 rpm and the cell- 
free SPN were tested at various dilutions against fresh Raji cells (2 x  103 cell/well). [3H]TdR 
was added for 7 h on day 5. The percent inhibition of isotope incorporation induced by the 
CCRF/CEM  SPN nonabsorbed (O), and adsorbed to Raji cells for 1 h at 4°C (I) or 1 h at 
37°C (&), is based on 188,000 cpm of the control Raji cultures incubated in medium alone. 
maximal inhibition of proliferation. To investigate the possibility that the inhib- 
itory factor partially or completely binds to the tumor target cells, cell-free SPN 
previously absorbed to Raji cells were tested against fresh Raji cultures at various 
dilutions. The  adsorbed SPN  were two to four orders of magnitude less active 
than  the  nonadsorbed  one  (Fig.  3),  indicating that  a  large  fraction  of  the 
inhibitory lymphokine was either inactivated by or adsorbed to the tumor target 
cells. 
IL-2  and  IFN assays.  To  investigate the  possibility that  either  IL-2  or  IFN 
were  at  least partly responsible for  the  inhibitory activity found in  the  T  cell 
leukemia-derived SPN, IL-2 and IFN assays (using cells with various degrees of 
sensitivity to IFN-c~; -3; or -3') were performed. Results clearly demonstrated the 
absence of these iymphokines both in the crude SPN from each T  leukemia cell 26  A T  CELL  LEUKEMIA-DERIVED SUPPRESSOR LYMPHOKINE 
line,  and  in  the  purified fractions obtained  from Jurkat  and  CCRF/CEM  cells 
(data not shown). 
Cell Cycle Analysis.  Kinetics studies with propidium iodide staining and flow 
cytometric analysis indicated that upon incubation with TLSL, three tumor cell 
lines (HL60, Daudi, ML3) accumulated in the G~ phase of the cell cycle, whereas 
Raji cells were arrested in the S phase.  A  representative experiment is depicted 
in  Fig.  4: after 7  d  in culture,  HL60 control cells (a) and HL60 cells incubated 
in the presence ofJurkat SPN (b) were 93% viable and could be found in each 
phase  of the  cell  cycle (~50%  in  G1,  26%  in  S,  and  20%  in  G2). In  contrast, 
HL60 cells incubated with CCRF/CEM  SPN (c) were <50%  viable than control 
cultures, and the viable cells were not dividing, being preferentially accumulated 
in the Gl phase of the cell cycle (___71% were in G1,  12%  in S, and  12%  in G2). 
Raji cells displayed a  different cell cycle pattern:  by day 7,  control cultures (a) 
were still highly viable and distributed as 59% in Gl,  16% in S, and 23% in G2. 
Raji cells incubated with Jurkat (b) or CCRF/CEM  SPN (c) had a  lower viability, 
and  were  46-51%  in  G1,  33-36%  in  S,  and  14-17%  in  G2.  Thus,  Raji  cells 
incubated with TLSL tend to accumulate in the S phase of the cell cycle. 
FIGURE 4.  Cell  cycle  analysis. HL60 and Raji cells were incubated at 2 x  105 cells/ml in T25 
plastic flasks ill medium alone (a) or in the presence of 10% crude SPN from Jurkat (b) or 
CCRF/CEM (c) cells. On day 7, cells were stained with propidium iodide and examined by 
tlow cytometry. Regions 1, 2, and 3 correspond to the G~, S, and G2 phases of the cell cycle, 
respectively. The histogram shows fluorescence intensity (abscissa) and the cell number values 
(ordinate). SANTOLI  ET  AL.  27 
Inhibition  of T Lymphocyte Activation.  To determine whether TLSL affects the 
proliferation  of hemopoietic  target  cells  other  than  ]eukemia/lymphoma  cell 
lines, we investigated the susceptibility to this factor of peripheral  blood mono- 
nuclear  cells induced  to  proliferate  in  vitro.  Two systems of T  cell activation 
were  analyzed,  one  in  response  to  alloantigens,  and  another  in  response  to 
mitogens.  While  the  SPN  from  Raji  and  Daudi  cells  had  no antiproliferative 
effect,  all  of  the  T  leukemia  cell-derived  SPN  abrogated  the  response  of 
lymphocytes to any stimulus  (Table  IV).  The  level of inhibition  was the same 
whether  TLSL  was added  at  the  start  or  24-48  h  after  the  initiation  of the 
cultures (data not shown).  Purified T  cells stimulated by PHA or in  MLC were 
inhibited to the same extent as unfractionated  PBL by all SPN tested except for 
the Jurkat  SPN  (data  not  shown).  Titration  studies  against  PHA-stimulated 
lymphocytes revealed that theJurkat and CCRF/HSB~ SPN were the least active 
(Fig.  5),  whereas  SPN produced  by CCRF/CEM  and  HUT-78 cell  lines  were 
again the strongest, resulting in >50% inhibition  at  10  -2.  Overnight incubation 
of freshly obtained  lymphocytes with  T  leukemia-derived  SPN  greatly dimin- 
ished or abolished  the proliferative response of these cells to PHA stimulation 
even after removal of the inhibitory SPN for the rest of the incubation period 
(Table V). Thus, short-term exposure of resting lymphocytes to TLSL severely 
affects their ability to respond to activation signals. 
Inhibition of Growth of CFU-GM and BFU-E.  The ability of TLSL  to inhibit 
normal mye]oid or erythroid colony formation was investigated. All of the crude 
SPN preparations  completely abrogated the growth of early (day 14) CFU-GM 
from peripheral blood of healthy donors, when tested up to 10 -4 dilution (Table 
VI). The  SPN from Jurkat,  HUT-78, and CCRF-CEM cell lines were the most 
active, being able to totally inhibit even at  10  -'~. Likewise, inhibition  of growth 
TABLE  IV 
Inhibition  of Mitogen- or Alloantigen-induced  T Cell Proliferation by 
T Leukemia-derived SPN 
SPN  PHA*  PWM*  MLC  ~ 
Jurkat  83.2 +  6.81  93.3 +  4.0  98.2 -+ 0.8 
CCRF/HSB2  91.4 ___ 3.1  92.5 +  4.4  91.0 +- 6.5 
JM  91.0 +  2.1  87.5 _+ 2.1  92.7 +  0.6 
HPB-ALL  91.2 +  5.0  88.0-+ 2.8  91.0 _+ 4.6 
MOLT-4  94.8 +  2.5  95.2_+  1.5  95.1  +  2.9 
HUT-78  93.8 -+ 2.8  90.1  _+  1.3  91.3 +  6.3 
CCRF/CEM  95.0 +  3.2  94.2 _  3.3  97.6 +-  1.4 
Raji  _<1.0  -<1.0  _<l.O 
Daudi  _<1.0  ~1.0  <1.0 
* PHA-stimulated PBL or purified T  lymphocytes were seeded at  1-2 × 
105 cells/well in the presence of  crude SPN (I : 10 dilution), and incubated 
for 3-4 d  before addition of [SH]TdR. 
$ PWM-stimulated PBL were plated as 1.5 x  I 05 cells/well and incubated 
for 6 d. 
§ MLC cultures were seeded as  1-1.5  ×  105 cells/well and incubated for 
6d. 
I Percent inhibition of proliferation observed in 3- l 0 experiments (mean 
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FIGURE 5.  Titration of the antiproliferative  activity of TLSL against stimulated lymphocytes. 
PBL (2 x  10 ~ cells/well in triplicate cultures) were incubated at 37°C in the presence of 1% 
PHA and  100-fold  dilutions of crude SPN  from Jurkat (O), HUT-78 (O), CCRF/HSB~  (F'I), 
MOLT-4 (I), HPB-ALL (A), CCRF/CEM (A), andJM (4~) T leukemia cell lines. [SH]TdR was 
added for 7 h on day 4. The percent inhibition of isotope incorporation is based on 173,500 
cpm of the control PHA-stimulated lymphocytes cultured without SPN. 
TABLE  V 
Inhibition of Mitogen Responsiveness upon Short-term Treatment of 
PBL with T Leukemia-derived  SPN 
SPN  [3H]TdR  Inhibition of 
incorporation  proliferation 
cpm  % 
Medium  97,439  -- 
Raft  94,557  3 
Jurkat  32,565  67 
MOLT-4  4,072  96 
CCRF/CEM  1,864  98 
PBL were incubated overnight at 37 °C in medium containing crude SPN 
(1:10 dilution). Lymphocytes were then washed four or five times, PHA 
(1%) was added, and the cultures were incubated (10 S cells/well) in the 
absence of inhibitory factors for 4 d before addition of [3H]TdR. 
of early CFU-GM  from bone marrow  could be seen with all of the SPN  (except 
forJM)  at least up to  10 -5 (Table VII). In contrast, bone marrow  late CFU-GM 
were sensitive only to higher concentrations of the SPN  (1:10 and in some cases 
1:100  dilutions)  (Table  VIII).  These  results  were  identical to  those  previously 
reported  for CIL (25). 
Experiments  in  which  peripheral  blood  CFU-GM  were  incubated  for  brief 
periods  of time  (1-12  h)  with  crude  SPN  at  1:10  and  1:I00  dilutions,  then 
washed free of SPN  and incubated for  14  d  more  with  CSF, indicated that  l-h 
exposure  of early CFU-GM  was  sufficient to initiate inhibition at  1:I0 dilution 
(Table  IX).  Nearly  complete  inhibition  of growth  was  observed  also at  i:I00 SANTOLI  ET  AL. 
TABLE  VI 
Titration of Colony-inhibiting Activity of T Leukemia-derived SPN 
Against Peripheral Blood CFU-GM 
SPN 
Colonies developing at SPN dilutions of: 
10-4  10-s  10-6 
jurkat  0*  3 ±  1  45 ±  I5 
CCRF/HSB2  11 ±  1  63 +  5  NT* 
JM  16 ±  4  70 ±  2  NT 
HPB-ALL  20 ±  6  44 ±  0  72 -+ 8 
MOLT-4  5 ±  5  54 ±  4  NT 
HUT-78  0  2 ±  0  65 ±  5 
CCRF/CEM  0  2 ±  2  71 -+ 27 
Peripheral blood mononuclear cells depleted of monocytes,  B, and T 
lymphocytes were cultured in 35-ram Petri dishes in medium containing 
CSF and crude SPN at various dilutions. CFU-GM-derived colonies were 
counted on day 14 using an inverted microscope. 
* Values represent the number of colonies scored in duplicate cultures 
(mean ±  SEM).  No colonies were detected in the cultures containing 
SPN at dilutions up to 10  -3. The number of colonies in control cultures 
(grown in the absence of SPN) was 80 ±  8  per  105 mononuclear cells 
plated. 
* NT, not tested. 
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TABLE  VII 
Titration of Colony-inhibiting Activity of T Leukemia-derived SPN 
Against Bone Marrow Early CFU-GM 
SPN 
Colony growth at SPN dilutions of: 
10-1  10-~  10-s  10-4  10-5 
Jurkat  0*  6 +  4  8 +  3  20 -+ 2  38 __+ 8 
CCRF/HSB2  0  4 __+ 1  NT*  20 _  5  36 ±  14 
JM  3 +  2  20 ±  6  NT  103 ___ 20  NT 
HPB-ALL  9+2  2±2  NT  34±  1!  37±7 
MOLT-4  0  5 ±  2  NT  24 ±  9  49 ±  4 
HUT-78  0  2 ±  2  NT  25 ±  11  37 ±  6 
CCRF/CEM  0  3 -4- 3  7 ±  2  30 ±  4  26 ±  8 
Bone marrow mononuclear cells depleted of adherent cells were cultured 
in  35-ram  Petri  dishes  in  medium  containing crude  SPN  at  various 
dilutions. Early CFU-GM-derived colonies were counted on day t 4. 
* Values represent the percentage of colony growth (mean _+ SEM) in the 
experimental cultures as compared to control cultures incubated in the 
absence of SPN. The number of colonies in control cultures were  123 
+  25 and 97  -+ 8  per  105 mononuclear cells in two experiments, with 
bone marrow samples from two different donors. 
NT, not tested. 
dilution  when  CFU-GM  were  exposed  to  the  inhibitory  factor  for  12  h  (Table 
IX).  These  results  suggest  that  TLSL  binds  to  the  target  cells  with  a  specific 
receptor  and,  in  a  fashion  similar  to  other  lymphokines,  initiates  a  series  of 
intracellular  events  that  result  in inhibition  of proliferation. 
The  conditioned  medium  from  the  T  leukemia  cell  lines  also  contained 
inhibitory  activity  against  the  growth  of  peripheral  blood  BFU-E.  Titration 30  A  T  CELL  LEUKEMIA-DERIVED  SUPPRESSOR  LYMPHOKINE 
TABLE  VIII 
Titration of Colony-inhibiting Activity of T Leukemia-derived SPN 
Against Bone Marrow Late CFU-GM 
SPN 
Colony growth at SPN dilutions of: 
10-1  10-2  10  -3 
Jurkat  0*  3 +  1  95 +  6 
CCRF/HSB2  0  70 +  6  99 +  8 
JM  1 +  2  105 +  12  NT* 
HPB-ALL  83 +  7  94 +  4  NT 
MOLT-4  0  93 +  7  NT 
HUT-78  0  81  +  5  NT 
CCRF/CEM  0  2 +  2  102 +  5 
Bone  marrow  cells depleted  of adherent cells were  cultured  in  Petri 
dishes in medium containing 10-fbld dilutions of crude SPN. Late CFU- 
GM-derived colonies were scored on day 7. 
* Values represent the percentage of colony growth (mean _+ SEM) in the 
experimental cuhures as compared to control cultures (no SPN added). 
The number of colonies in control cultures was 254 _+ 4 and  132 +  7 
per 105 mononuclear cells in two experiments with bone marrow samples 
from two different donors. 
* NT, not tested. 
TABLE  IX 
Inhibition of Growth of Peripheral Blood CFU-GM after Brief(1 and 
12 h) Exposure to T Leukemia-derived SPN 
SPN  Dilutions 
Numbers of colonies after ex- 
posure (h) to SPN: 
1  12 
Control mediun/  --  397 +  1"  491  ±  9 
Jurkat  10  -I  92 +- 20  7 --- 7 
10  -2  396 +  40  6 +  2 
CCRF/CEM  10  -1  400 +  20  6 +  4 
10  -2  416 +  40  213 +  7 
HUT-78  10  -1  271 +- 125  167 +  35 
10  -2  412 +  34  NT* 
Peripheral blood mononuclear cells depleted of adherent and phagocytic 
cells and of B and T  lymphocytes were  incubated for  1 or  12  h  with 
10 -1 and 10  -2 dilutions of crude SPN, washed extensively and plated at 
150,000/Petri dishes. Colonies were counted after 14 d incubation. 
* Values represent the  number of CFU-GM-derived colonies scored in 
duplicate cultures (mean "4- SEM). 
* NT, not tested. 
studies  showed  that  almost  a  total  inhibition  of growth  was  obtained  with  these 
SPN  up to  10 -5 dilution  (Table  X). 
Partial Purification and Physicochemical Characterization.  Partial  characteriza- 
tion of the  inhibitory  activity was achieved  by gel filtration  on a  Sephacryl  S-300 
column  of  ammonium  sulfate-precipitated  SPN  (Fig.  6A).  The  SPN  derived 
from  Jurkat  and  CCRF/CEM  cells  were  chosen  because  of  their  narrow  and 
broad  spectrum  of  reactivity,  respectively,  against  the  target  cell  lines  studied 
(Table  I).  All fractions  from  each  SPN  were  tested  against  the highly  susceptible SANTOLI  ET  AL.  31 
TABLE  X 
Inhibition of Growth of Peripheral Blood BFU-E by 
T Leukemia-derived  SPN 
Number of BFU-E-  SPN  Dilutions 
derived colonies 
Control medium  --  206 4- 5.3* 
Jurkat  10 -2  0 
10 -3  0 
10 -4  14-1 
10  -5  74-4 
CCRF/CEM  10 -2  0 
10 -s  0 
10 -4  1 +  1 
10  -5  11  4-2 
Peripheral  blood  mononuclear cells  depleted  of monocytes, T,  and  B 
lymphocytes were plated at  10 5 cells/Petri dish in methylcellulose in the 
presence of various SPN concentrations, BPA, and erythropoietin. BFU- 
E-derived colonies were scored after  14 d  of incubation. 
* Values  represent the  number of colonies scored  in  duplicate  cultures 
(mean +  SEM). 
Daudi  cells  in  a  5-d  proliferation  assay.  The  inhibitory activity produced  by 
CCRF/CEM cells (TLSLc~:M) eluted in two peaks, one of Mr 88,000, correspond- 
ing to fractions  18-21  (pool A), and one in the void volume of Mr -> 300,000, 
which corresponded to  fractions 9  and  10  (pool  B) (Fig.  6A).  In contrast, the 
activity produced by Jurkat cells (TLSLj°) eluted in a single peak of Mr 88,000, 
with no detectable activity in the void volume (Fig. 6A). When tested against the 
entire panel of hemopoietic tumor cell lines, neither the crude SPN nor the A 
or B  pools  derived from Raji  cells inhibited proliferation (Table  XI).  Pool  A 
from TLSLjo inhibited only the B lymphoblastoid lines Raji,  Daudi, and BL2, 
which are sensitive to the crude Jurkat SPN (Tables I and XI). In contrast, both 
pools A and B of TLSLc~-M inhibited the proliferation of all hemopoietic tumor 
cell  lines.  Whereas  pool  A  of TLSLcEM  remained active at  a  1:100  dilution, 
neither  pool  B  of  TLSLc~:M  nor  pool  A  of TLSLjL,  did  (data  not  shown). 
Consequently, CCRF/CEM cells not only produced two forms of TLSL activity 
of high and low Mr, but generated more of the low-Mr factor than Jurkat cells; 
furthermore, CCRF/CEM  cells produced more low- than high-Mr factor when 
grown in synthetic medium. 
To determine whether the high-M, form of TLSLcEM is distinct from the low- 
M,. form, or represents an aggregate, we generated TLSLcEM-Containing SPN in 
medium containing 5%  FBS  to  favor aggregate formation before ammonium 
sulfate  precipitation.  An  aliquot  of resuspended precipitate  was  dialyzed and 
fractionated  in  PBS.  Unlike  the  gel  filtration  of TLSLcEM  generated  in  the 
absence of serum, substantially more activity remained in the high-Mr fractions 
as compared to the low-Mr fractions at  1:100  dilution (Fig.  6B).  Furthermore, 
once formed, the aggregates could be disassembled by either detergent (Fig. 6 B 
and C) or high salt (C), with the result that more TLSL activity appeared in the 32  A  T  CELL  LEUKEMIA-DERIVED  SUPPRESSOR  LYMPHOK1NE 
100 
80 
6O 
4O 
2O 
0 
IO0 
8O 
2O 
0 
/ 
\ 
\ 
i  i  I  i  J 
80  /  ~,,  / 
h  i  [ 
0  5  10  15  20  25  30 
Fraction  number 
FIGURE 6.  (A) Inhibition of Daudi cell proliferation by fractionated TLSL from CCRF/CEM 
(Q) and Jurkat (©)generated in synthetic medium. Crude SPN from Jurkat and CCRF/CEM 
cells grown in synthetic medium were precipitated in 85% ammonium sulfate, dialyzed, and 
placed on a  1.5 x  50 cm Sephacryl S-300 column equilibrated with PBS. 3-ml fractions were 
collected at a  flow rate of 10 ml/h. Daudi cells (2 ×  104 cells/well in triplicate culture) were 
incubated in complete RPMI-1640 medium containing I:10 dilution of each fraction, pulsed 
on day  5  with [3H]TdR and harvested 7  h  later. Arrows indicate fractions containing blue 
dextran  (BD) and  molecular weight  markers.  (B)  Inhibition of Daudi  cell  proliferation by 
fractionated TLSLcE~  generated  in  serum-containing medium.  Conditioned medium  from 
CCRF/CEM  cells containing 5%  FBS was precipitated in  85% ammonium sulfate,  dialyzed 
against the  appropriate  solution,  and  placed  on  a  1,5  ×  50  cm  Sephacryl  S-300  column 
equilibrated with PBS (I) or PBS plus 0.02% Tween-20 (F-I). 3-ml fractions were collected at 
a flow rate of 10 ml/h. Every other fraction was tested for TLSL activity by incubating Daudi 
cells (2 ×  104 cells/well in triplicate culture) in complete RPMI-1640 medium containing 1:100 
dilution of the fraction sample, followed by incubation and pulsing as above. (C) Inhibition of 
PHA-induced  T  lymphocyte  proliferation  by  fractionated  TLSLcrM  generated  in  serum- 
containing medium. Conditioned medium of CCRF/CEM containing 5%FBS was precipitated 
in 85% ammoniunl sulfate, dialyzed against the appropriate solution, and placed on a  1.5 X 
50 cm Sephacryl S-300 column equilibrated with PBS (I), PBS plus 0.5%  NaC1 (A), or PBS 
plus 0.02% Tween-20 (El). 3-ml fractions were collected at a flow rate of 10 ml/h, and every 
other fraction was tested for TLSL activity at 1:10 dilution, as above. SANTOLI  ET  AL. 
TABLE  Xl 
Antiproliferative Activity of Fractions Obtained  from Gel Filtration of 
T Leukemia-derived SPN 
33 
SPN  Raji  Daudi  BL2  HL60  ML3  U937  K562  BV-173 
Raji  Crude  _1"  _<1  _<1  _<1  _<1  _<1  -<I  -<1 
Pool A*  _<1  _<1  _<1  _<1  _<1  _<1  _<1  _<1 
Pool B  _<1  _~1  61  _-<1  _<1  _<1  _<1  _<1 
Jurkat Crude  83  93  40  ---1  -<1  -~1  <-1  ~1 
Pool A  99  97  97  -<1  <-1  <-1  <-1  <-1 
Pool B  10  -1  6  _-%1  <-1  -<1  <-1  <1 
CCRF/CEM Crude  94  97  94  81  99  89  99  97 
Pool A  99  99  98  42  57  51  95  88 
Pool B  74  66  50  35  41  13  55  82 
Target cells (2-4 ×  103 cells/well) were incubated in microplates in the presence of 1:10 dilution 
of either crude SPN or their pooled A and B fractions (triplicate cultures). After a 5-d incubation 
at 37°C, [3HITdR incorporation was measured. 
* Percent inhibition of proliferation (mean from two or three experiments). 
* Pool  A  (fractions  18-21)  correspond to  the  peak  of Mr  88,000  Pool  B  (fractions 9  and  10) 
correspond to the peak in the void volume of Mr >300,000. 
fractions containing the smaller form of TLSL.  These results suggest that the 
high-Mr component of TLSLc~M  is an aggregate of the low-Mr  form and  the 
relative amounts of each detected is dependent on the producer cell line, as well 
as the conditions used in production and processing of the supernatants. 
Under standard column chromatography conditions, partially purified TLSLju 
did not bind to  lectins covalently bound to Sepharose, including wheat germ, 
lens cu]inaris, and concanavalin A (data not shown). 
Physicochemical studies were performed to analyze the stability of TLSL at 
various temperature and pH conditions. Titration experiments against Raji cells 
demonstrated that  the activity of crude TLSLcv.M was (a) totally destroyed by 
exposure to 56°C for 30 rain, or 75°C for 15 min, and (b) at least two to four 
orders of magnitude less active upon brief (10  rain) exposure to  low (3),  and 
high (8.5) pH.  Thus, TLSL is very sensitive to heat denaturation and unstable 
to extremes of pH.  The isoelectric point of crude TLSLcEM  and TLSLju was 
found  to  be  5.2-5.3,  as  determined  by  flat-bed  electrofocusing in  Bio-lyte 
electrofocusing gel  (Bio-Rad)  with  an  LKB  2117  multiphor apparatus  (LKB, 
Bromma, Sweden) (42). 
Discussion 
In  this  study we  have shown  that  unstimu]ated  human  leukemia cell  lines, 
(Jurkat,  CCRF/HSB2,  JM,  HPB-ALL,  MOLT-4,  HUT-78,  and  CCRF/CEM) 
release into their medium a  factor that inhibits hemopoietic cells of lymphoid, 
granulocytic, erythrocytic, and  monocytic origin.  The ability to  produce this 
lymphokine is  restricted to leukemic cells of the T  lymphocytic lineage as no 
such factor could be detected in the conditioned medium of either monocytic, 
myeloid, or B ]eukemia/]ymphoma  cell lines. No correlation was found between 
the T  cell phenotype of the lymphokine producer cell lines and their ability to 34  A  T  CELL  LEUKEMIA-DERIVED  SUPPRESSOR  LYMPHOKINE 
produce low or high  titers of TLSL (data not shown). Titration  studies against 
very sensitive target cells, such as Raji and PHA-activated lymphocytes, showed 
that the supernatant  from the Jurkat cell line was the least active, and the ones 
from HUT-78, CCRF/CEM, and MOLT-4 cells were the most active. The lower 
activity of the factor produced by Jurkat cells can explain the apparent selective 
inhibition  of proliferation  of the most sensitive targets (B cell lines) and not of 
more resistant targets (cell lines of myeloid, erythroid, and monocytic lineage). 
Studies  reported  so far  (9-23)  on  the  effect of inhibitory  tymphokines  on 
normal and leukemic hemopoietic cells have been incomplete, most of the studies 
limiting the target sensitivity analysis to B or T  cell lines. TLSL is distinct from 
BIF because BIF is ineffective against  MOLT-4,  HSB2, Daudi, and  K562 cells 
and  is  stable  at  pH  2  and  at  56°C  for  30  min  (17).  TLSL  is  biochemicaIly 
separable from SIF (18-29  kD by gel filtration)  and SIRS (110-150  kD by gel 
filtration) (12,  13, 23). 
TLSL is not SISS-T (30-45 kD), which specifically suppresses T  ~:e]l prolifer- 
ation and requires adherent  macrophage cells for its activity (15). TLSL is also 
distinct from SISS-B (60-80 kD) because the latter is stable at pH 2.5 and acts 
only on B cells arresting their Ig production (16). It is not LT because (a) LT is 
heat stable at  75°C  over  15-rain  incubation,  and  is a  glycoprotein (7,  8) while 
TLSL is not; (b) LT is directly cytotoxic whereas TLSL arrests cell proliferation 
without lysing the target cells; (c) mouse L cells, which are very sensitive to LT 
(6), are completely insensitive to TLSL; (d) monomeric  LT has a Mr of 25,000 
(8) rather than 45,000 as seen with TLSL. 2 
TLSL  has  some  characteristics  in  common  with  IDS,  a  factor  released  by 
activated T  lymphocytes, such as the  ability to inhibit  [3H]TdR incorporation 
without  causing  cell  death  (10).  IDS,  however,  is  a  glycoprotein,  has  a  lower 
isoelectric point of 2.5,  and  its subunits are of 20 kD (43).  It is  impossible to 
compare the respective cell target  range  since most studies on  IDS have been 
limited  to  HeLa  cells  and  to  mitogen-stimulated  lymphocytes  (10,  11).  The 
designation of IDS has also been ascribed to the product of the macrophage-like 
cell line  U937 (44).  This monokine,  released either spontaneously or in  larger 
quantities  upon  mitogenic  stimulation  by  U937  cells,  shares  with  TLSL  the 
characteristics of heat and acid lability, and the nontoxic mechanism  of action; 
however, unlike TLSL, IDS has an Mr of 65,000 by gel filtration. Most important, 
its inhibitory activity is reversible, and is directed only against cells of lymphoid 
origin (mitogen-induced PBL and some neoplastic T  and B cell lines). 
TLSL is similar to CIL (25), based on its Mr by gel filtration and on its ability 
to inhibit hemopoietic colony growth in a variety of leukemic cell lines. However, 
at difference with CIL, which in preliminary  studies appeared to preferentially 
inhibit the proliferation of cells bearing surface class II HLA (Ia) antigens (25), 
TLSL inhibits cell growth regardless of the expression of HLA-D gene products 
on the target cells: the cell lines K562, HL60, ML3, U937, which do not express 
or only weakly express Ia antigens  (45),  were actually inhibited  by most of the 
SPN in our study. The possibility that TLSL induces the expression of Ia antigens 
2 Tweardy,  D. J., J. J.  Earley,  D.  Santoli,  B.  Dietzschold,  M. J.  Wheelock, S.  Altmann,  B.  L. 
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on  myelomonocytic cells similar  to  that  described  for differentiation-inducing 
factor (DIF) (45) and for IFN-~, (46, 47) can be ruled out, as immunofluorescence 
analysis  did  not  reveal  the  increase  nor  the  appearance  of any  HLA-D  gene 
product on cells incubated with TLSL for up to 5 d (data not shown). 
Finally,  TLSL  has  some  similarity  with  SAF,  a  factor  produced  by a  6TG- 
resistant clone of the CEM cell line. TLSL, like SAF, inhibits [~H]TdR incorpo- 
ration  by T  cells at  very  low  dilutions  (up  to  10  -~)  (18,  19),  and  arrests  cell 
proliferation in the G1 phase of the cell cycle. The larger Mr (>200,000) observed 
for SAF (19) could be ascribed to aggregation  phenomena  of this  iymphokine 
when run on column chromatography in the presence of serum, as we observed 
with TLSL. TLSL has the same isoelectric point as SAF and the same sensitivity 
to heat inactivation. TLSL, however, clearly acts directly on the tumor cell lines, 
while no information  is available on the activity of SAF against these targets.  In 
addition, SAF acts by activating a suppressor factor produced by normal T  cells, 
whereas the mechanism by which TLSL inhibits the proliferation of mitogen- or 
alloantigen-stimulated  lymphocytes and of hemopoietic progenitor cells has yet 
to be determined. 
Although  TLSL is produced in large amounts by T  leukemia cell lines, some 
of these producer  lines are sensitive to high  concentrations  of the factor.  The 
intermediate producer CCRF/HSB2 cell line was partly inhibited by the condi- 
tioned medium of the high-producer  HUT-78, CCRF/CEM, and MOLT-4 cell 
lines, and the  low-producer Jurkat was inhibited by all of the SPN except by its 
own. Moreover, partially purified concentrated TLSLju inhibited all T  cell lines 
tested,  including Jurkat cells themselves.  This  observation  suggests that  the T 
leukemia  cell  lines  producing  TLSL  might  also  produce  adequate  levels  of 
another factor that protects them from the inhibitory activity of TLSL. 
The kinetics data indicated that,  unlike human  LT and tumor necrosis factor 
(TNF),  which  are  directly  cytotoxic against  neoplastic  cells  (8,  48),  TLSL  is 
cytostatic, and cell death occurs subsequent to proliferative arrest. In fact, during 
the first 2  or 3 d  of incubation  in the presence of TLSL, the cells grow at the 
same rate as the control cultures;  maximal  inhibition  of proliferation occurs on 
day 4 or 5, and is not accompanied by a great loss of cell viability; the cells die 
shortly after they have ceased dividing. A similar pattern of cell growth inhibition 
was observed in methylcellulose under conditions of single-cell culture, indicating 
that TLSL also abrogates the clonogenic potential of tumor cells. 
With the exception of Raji cells that  accumulated in the S phase,  the tumor 
target  cells incubated  with  TLSL  were arrested  in  the  postmitotic,  pre-DNA 
synthesis interval  corresponding  to the  G0-G1 phase of the cell cycle, in which 
cellular  commitment  to proliferation  is made (49).  Neoplastic cells exposed to 
IFN-3, and  LT in combination also accumulate in that phase and cease dividing 
(50);  likewise,  all  terminally  differentiated  cells are  arrested  in  the  Go phase. 
Maximal inhibition of proliferation occurred when TLSL was present through- 
out the 5-d incubation; however, the proliferative ability of all the tumor target 
cells  was  sharply  reduced  even  after  a  very  brief exposure  to  the  inhibitory 
lymphokine.  This  observation,  together  with  the  kinetics  data  of inhibition  of 
growth  in  liquid  and  semisolid cultures,  indicated  that,  although  the  ceils can 
normally replicate for a few days after treatment, TLSL does bind readily to the 36  A  T  CELL  LEUKEMIA-DERIVED  SUPPRESSOR  LYMPHOKINE 
cell membrane,  and delivers the signal  to cease dividing.  The observation that 
overnight exposure of PBL to the T  leukemia-derived SPN results in partial or 
total  inhibition  of their  proliferative  response  to  PHA  might  reflect  TLSL- 
induced structural alterations on the cell surface that in some way abrogate lectin 
binding  or  [3H]TdR  uptake  by  lymphocytes.  A  similar  mechanism  could  be 
responsible for the inability of blood and  bone marrow CFU-GM or BFU-E to 
respond to CSF or BPA after overnight incubation with the T  ceil-derived SPN. 
TLSLju  has  now  been  purified  to  homogeneity  2 and  subjected  to  amino- 
terminal sequence analysis. Based on that analysis, on Mr determinations by SDS- 
PAGE and gel filtration,  and on the functional and physicochemical character- 
istics presented  in  this  study,  TLSL can  be distinguished  from  the  three best- 
characterized  human  antitumor  agents:  LT  (7,  8),  IFN-3,  (1,  2),  and  tumor 
necrosis factor (TNF) (51). 
Summary 
Human  T  leukemia  cell  lines  spontaneously  release  into  their  medium  a 
suppressor  lymphokine,  T  leukemia-derived  suppressor  lymphokine  (TLSL), 
able to inhibit proliferation,  DNA synthesis,  and colony formation  in a  variety 
of  malignant  hemopoietic  cell  lines,  as  well  as  in  normal  myelomonocytic 
progenitor  cells  from  bone  marrow  and  peripheral  blood.  Titration 
curves indicated  that  the  inhibitory activity in  the crude supernatant  prepara- 
tions  ranged  from  10-~-10-9:  the  supernatants  from  CCRF/CEM,  HUT-78, 
and  MOLT-4 cell  lines  were the  most active,  those  from  HPB-ALL, JM,  and 
CCRF/HSBz displayed an intermediate activity, and the Jurkat supernatant  was 
the least active. Target cell lines of B cell origin (Burkitt lymphomas) were more 
sensitive than  granulocytic, monocytic, erythroid,  and T  cell lines.  Partial puri- 
fication  by ammonium  sulfate precipitation  and column chromatography dem- 
onstrated  that  TLSL is a  protein  with an Mr of 88,000,  as determined  by gel 
filtration.  A  high M,. form (>300,000)  was produced in serum-free medium  by 
one of the most active producer cell lines (CCRF/CEM), and appeared to be an 
aggregate of the 88,000 Mr form. Neither the partially purified fractions obtained 
nor the crude supernatant  preparations displayed antiviral activity or contained 
interleukin 2. Unlike lymphotoxin and tumor necrosis factor, TLSL is cytostatic: 
maximal inhibition  of proliferation  was observed 4-5 d after addition of crude 
supernatant  to the target cells, and was not accompanied by a significant loss in 
cell  viability.  The  antiproliferative  capacity of TLSL  was  manifested  both  in 
suspension and methylcellulose cultures. Treated target cells accumulated either 
in the G1 or in the S phase of the cell cycle. The effect of TLSL on the target 
cells  is  irreversible:  even  brief (1  h)  incubation  of sensitive  cells  with  TLSL 
resulted  in  inhibition  of proliferation  measured  5  d  later.  Although  TLSL  is 
produced  by  leukemic  T  cell  lines,  this  lymphokine  inhibits  proliferation  of 
normal  peripheral  blood  T  cells  in  response  to  mitogens  or  alloantigens:  T 
lymphocyte activation  was inhibited by all of the T  cell supernatants  tested.  Ill 
contrast,  when T  cell  lines were used as targets,  no inhibition  of proliferation 
was detected with  two exceptions:  the low producer Jurkat cell line was sensi- 
tive  to  all  the  T  cell-derived  supernatants,  and  the  intermediate  producer SANTOLI  ET  AL.  37 
CCRF/HSB2 cell  line was sensitive only to the  three most active supernatants, 
CCRF/CEM,  MOLT-4, and HUT-78. 
Tbe possible significance of TLSL and  its relationship with other suppressor 
lymphokines previously described in other systems is discussed. 
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